The Real Reason Medicine Is Unaffordable in America

Quick Overview

The unaffordability of medicine in America stems from a self-perpetuating loop involving taxpayer funding of NIH research, university patenting, pharmaceutical licensing, FDA blocking competition, and lobbying, which ultimately allows large pharmaceutical companies to maintain monopolies and charge exorbitant prices while consumers pay three times: as taxpayers, at the pharmacy, and as voters.

Key Points: One vial of Humalog costs $3 to manufacture but sells for a massive markup due to systemic issues, not production cost. The price of insulin has increased by nearly 700% between 1996 and 2020, far outpacing general inflation ($35 vs $275). The system relies on three main pillars: FDA (blocking competition), Intellectual Property Laws (granting monopolies), and Lobbying (protecting the system). 99.4% of FDA-approved drugs between 2010 and 2019 had NIH taxpayer funding, meaning the public paid for the foundational research. Pharmaceutical lobbying spending is massive, reaching a record $5 billion in 2025 (a 14% year-over-year increase), which protects their monopolies. For every $100 spent on drugs, manufacturers only receive $59 in revenue; $25 goes to Pharmacy Benefit Managers (PBMs) as profit. Alternatives like generic/biosimilar drugs exist but are suppressed because the FDA's high filing costs ($4.3 million with clinical data) and regulatory hurdles are designed to protect incumbent monopolies.

Context: The video analyzes the systemic reasons behind the high cost of essential medicines, particularly insulin, in the United States, contrasting manufacturing costs with final consumer prices. It introduces a six-part 'loop' involving government agencies, universities, and pharmaceutical companies that allegedly keeps prices artificially high and stifles competition, using examples like the discovery of insulin over a century ago to illustrate the long-term nature of the problem.

Detailed Analysis

The central argument of the video is that medicine, using insulin as a prime example, is unaffordable in America due to a systemic loop designed to protect corporate profits rather than public health. The cost to manufacture a vial of insulin is cited as merely $3, yet it sells for hundreds of dollars, an increase far exceeding general inflation over the past two decades. The speaker identifies three main pillars supporting this system: the FDA, which blocks competition by maintaining high regulatory barriers (like the $4.3 million filing fee for drugs with clinical data); Intellectual Property Laws, which grant monopolies; and lobbying, which protects the system. The video details how taxpayers fund the initial research via the NIH (99.4% of FDA-approved drugs had NIH funding between 2010-2019), universities patent the research, and pharmaceutical companies then license these patents. The FDA then blocks generic competitors, allowing the patent holder to charge monopoly prices. Furthermore, lobbying spending by big pharma and other industries (like realtors) is shown to be massive, reaching a projected $5 billion in 2025, which reinforces these protective laws. The pie chart data reveals that for every $100 spent on drugs, only $59 reaches the manufacturer, with PBMs taking $25 in profit. The speaker concludes that the solution is not more government involvement but rather dismantling these artificial constraints to allow free-market competition, which would naturally drive prices down, as seen in other industries like electronics where competition has caused prices to plummet.